EICHOR
● Enrolling By Invitation
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Condition: Acute Myocardial Infarction · Sponsor: Viatris Innovation GmbH
About this study
This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (821)
| Advanced Cardiovascular, LLC | Alexander City, Alabama, United States | — |
| Birmingham VA Health Care System | Birmingham, Alabama, United States | — |
| Cardiovascular Associates of the Southeast | Birmingham, Alabama, United States | — |
| Grandview Medical Center and Affinity Cardiovascular Specialists, LCC | Birmingham, Alabama, United States | — |
| Heart Center Research, LLC | Huntsville, Alabama, United States | — |
| Dignity Health Mercy Gilbert Medical Center | Gilbert, Arizona, United States | — |
| Mayo Clinic Arizona | Phoenix, Arizona, United States | — |
| University of Arizona - Sarver Heart Center | Tucson, Arizona, United States | — |
| Amicis Research Center. | Anaheim, California, United States | — |
| John Muir Health | Concord, California, United States | — |
| Profound Research LLC at San Diego Cardiovascular Associates | La Jolla, California, United States | — |
| San Francisco VA Health Care System" | San Francisco, California, United States | — |
+ 809 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.